Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...

Drugs and weight loss often go hand in hand, but the journey can feel overwhelming—especially when your wallet takes a hit.

Newer medications to treat diabetes and obesity are saving lives, but those who need the injectable drugs the most, were the ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Lilly's Q3 revenue and earnings miss primarily stemmed from lower-than-expected sales of Mounjaro and Zepbound. Should ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

JPMorgan analyst Chris Schott views the post-earnings weakness in Eli Lilly (LLY) shares as a buying opportunity. While the results missed ...

The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.

Dow, S&P 500, and Nasdaq futures are falling in premarket trading as Big Tech earnings spook the stock market.

Eli Lilly reported third-quarter earnings and revenue below Wall Street expectations, reducing its full-year adjusted profit ...